Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
13
HOOK Quote, Financials, Valuation and Earnings
Last price:
$1.14
Seasonality move
:
-19.92%
Day range:
$1.14 - $1.18
52-week range:
$0.72 - $6.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.53x
P/B ratio:
0.41x
Volume:
82.5K
Avg. volume:
63.2K
1-year change:
-82.73%
Market cap:
$13.9M
Revenue:
$43.9M
EPS (TTM):
-$5.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma
|
$3.4M | -$0.64 | 161.63% | -59.87% | $2.00 |
|
GILD
Gilead Sciences
|
$6.9B | $1.96 | -0.13% | 51.38% | $116.85 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
POAI
Predictive Oncology
|
$1.5M | -- | -25.85% | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
|
VIGL
Vigil Neuroscience
|
-- | -$0.47 | -- | -9.62% | $9.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma
|
$1.14 | $2.00 | $13.9M | -- | $0.00 | 0% | 1.53x |
|
GILD
Gilead Sciences
|
$109.85 | $116.85 | $136.6B | 23.13x | $0.79 | 2.84% | 4.82x |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
POAI
Predictive Oncology
|
$0.78 | -- | $7M | -- | $0.00 | 0% | 3.62x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
|
VIGL
Vigil Neuroscience
|
$8.07 | $9.52 | $376.6M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma
|
-- | 3.199 | -- | 2.92x |
|
GILD
Gilead Sciences
|
56.56% | 0.135 | 17.9% | 1.00x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
POAI
Predictive Oncology
|
-- | 0.261 | -- | 0.68x |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
|
VIGL
Vigil Neuroscience
|
-- | 10.653 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma
|
-- | -$17.5M | -105.09% | -105.43% | -769.81% | $32K |
|
GILD
Gilead Sciences
|
$5.1B | $2.5B | 13.82% | 32.29% | 28.63% | $1.7B |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
POAI
Predictive Oncology
|
$65.2K | -$2.3M | -529.75% | -557.45% | -2073.29% | -$985.8K |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
|
VIGL
Vigil Neuroscience
|
-- | -$23.5M | -- | -- | -- | -$24.2M |
HOOKIPA Pharma vs. Competitors
-
Which has Higher Returns HOOK or GILD?
Gilead Sciences has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of 19.72%. HOOKIPA Pharma's return on equity of -105.43% beat Gilead Sciences's return on equity of 32.29%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.23 $34.1M GILDGilead Sciences76.9% $1.04 $44B -
What do Analysts Say About HOOK or GILD?
HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 75.44%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 6.37%. Given that HOOKIPA Pharma has higher upside potential than Gilead Sciences, analysts believe HOOKIPA Pharma is more attractive than Gilead Sciences.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma0 1 0 GILDGilead Sciences16 11 0 -
Is HOOK or GILD More Risky?
HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.
-
Which is a Better Dividend Stock HOOK or GILD?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or GILD?
HOOKIPA Pharma quarterly revenues are $2M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. HOOKIPA Pharma's net income of -$15.4M is lower than Gilead Sciences's net income of $1.3B. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 23.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.53x versus 4.82x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma1.53x -- $2M -$15.4M GILDGilead Sciences4.82x 23.13x $6.7B $1.3B
-
Which has Higher Returns HOOK or NBY?
NovaBay Pharmaceuticals has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of -49.65%. HOOKIPA Pharma's return on equity of -105.43% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.23 $34.1M NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About HOOK or NBY?
HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 75.44%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that HOOKIPA Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe HOOKIPA Pharma is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma0 1 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is HOOK or NBY More Risky?
HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock HOOK or NBY?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or NBY?
HOOKIPA Pharma quarterly revenues are $2M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. HOOKIPA Pharma's net income of -$15.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.53x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma1.53x -- $2M -$15.4M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns HOOK or POAI?
Predictive Oncology has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of -2214.55%. HOOKIPA Pharma's return on equity of -105.43% beat Predictive Oncology's return on equity of -557.45%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.23 $34.1M POAIPredictive Oncology59.1% -$0.34 -$145.8K -
What do Analysts Say About HOOK or POAI?
HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 75.44%. On the other hand Predictive Oncology has an analysts' consensus of -- which suggests that it could grow by 283%. Given that Predictive Oncology has higher upside potential than HOOKIPA Pharma, analysts believe Predictive Oncology is more attractive than HOOKIPA Pharma.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma0 1 0 POAIPredictive Oncology0 0 0 -
Is HOOK or POAI More Risky?
HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Predictive Oncology has a beta of 1.176, suggesting its more volatile than the S&P 500 by 17.559%.
-
Which is a Better Dividend Stock HOOK or POAI?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Predictive Oncology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or POAI?
HOOKIPA Pharma quarterly revenues are $2M, which are larger than Predictive Oncology quarterly revenues of $110.3K. HOOKIPA Pharma's net income of -$15.4M is lower than Predictive Oncology's net income of -$2.4M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Predictive Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.53x versus 3.62x for Predictive Oncology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma1.53x -- $2M -$15.4M POAIPredictive Oncology3.62x -- $110.3K -$2.4M
-
Which has Higher Returns HOOK or TOVX?
Theriva Biologics has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of --. HOOKIPA Pharma's return on equity of -105.43% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.23 $34.1M TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About HOOK or TOVX?
HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 75.44%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than HOOKIPA Pharma, analysts believe Theriva Biologics is more attractive than HOOKIPA Pharma.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma0 1 0 TOVXTheriva Biologics1 1 0 -
Is HOOK or TOVX More Risky?
HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock HOOK or TOVX?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or TOVX?
HOOKIPA Pharma quarterly revenues are $2M, which are larger than Theriva Biologics quarterly revenues of --. HOOKIPA Pharma's net income of -$15.4M is lower than Theriva Biologics's net income of -$4.3M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.53x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma1.53x -- $2M -$15.4M TOVXTheriva Biologics0.33x -- -- -$4.3M
-
Which has Higher Returns HOOK or VIGL?
Vigil Neuroscience has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of --. HOOKIPA Pharma's return on equity of -105.43% beat Vigil Neuroscience's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.23 $34.1M VIGLVigil Neuroscience-- -$0.49 -- -
What do Analysts Say About HOOK or VIGL?
HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 75.44%. On the other hand Vigil Neuroscience has an analysts' consensus of $9.52 which suggests that it could grow by 18.02%. Given that HOOKIPA Pharma has higher upside potential than Vigil Neuroscience, analysts believe HOOKIPA Pharma is more attractive than Vigil Neuroscience.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma0 1 0 VIGLVigil Neuroscience0 8 0 -
Is HOOK or VIGL More Risky?
HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Vigil Neuroscience has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HOOK or VIGL?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vigil Neuroscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Vigil Neuroscience pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or VIGL?
HOOKIPA Pharma quarterly revenues are $2M, which are larger than Vigil Neuroscience quarterly revenues of --. HOOKIPA Pharma's net income of -$15.4M is higher than Vigil Neuroscience's net income of -$22.4M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Vigil Neuroscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.53x versus -- for Vigil Neuroscience. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma1.53x -- $2M -$15.4M VIGLVigil Neuroscience-- -- -- -$22.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
